Bone News and Research

RSS

LabelDataPlus online drug label database launched by Reed Technology and Information Services

Reed Technology and Information Services Inc., a LexisNexis® business, today announced the introduction of LabelDataPlus™ – a comprehensive drug label database available on the Web for both industry and consumer use. LabelDataPlus offers more than 5,000 current and archived FDA-approved drug labels – the same drug information found on the National Library of Medicine’s DailyMed web site – combined with powerful search features that unlock the information contained in drug labels (package inserts).

28 Oct 2009

NCI awards UAMS Myeloma Institute $19.5M grant

The internationally known multiple myeloma program at the University of Arkansas for Medical Sciences (UAMS) will receive $19.5 million over five years to continue work that has already developed new treatments for this cancer of plasma cells, a type of white blood cell present in the bone marrow.

28 Oct 2009

MedX Health signs marketing agreement with MMB GmbH

MedX Health Corp., a global leader in developing drug free, non-invasive, low level laser and light therapy for tissue repair and pain relief, today announced that the company will be expanding its sales and marketing efforts with the new European master distributor MMB GmbH.

28 Oct 2009

ACS podcast on medical adhesive

Scientists questing after a long-sought new medical adhesive describe copying the natural glue secreted by a tiny sea creature called the sandcastle worm in the latest episode in the American Chemical Society's (ACS) award-winning podcast series, "Global Challenges/Chemistry Solutions."

28 Oct 2009

RTI Biologics revenues increases to $42.8 million in third quarter 2009

RTI Biologics Inc., a leading processor of orthopedic and other biologic implants, reported operating results for the third quarter ended Sept. 30, 2009.

28 Oct 2009

Third quarter 2009 financial results announced by DJO

DJO Incorporated (“DJO” or the “Company”), a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC (“DJOFL”), for the third quarter of 2009, ended September 26, 2009.

28 Oct 2009

First spinal surgery in the U.S. using Osteotech's MagniFuse PC bone graft technology performed

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that MagniFuse PC (Posterior Cervical) Bone Graft, a new tissue-based product built upon the Company's proprietary MagniFuse bone graft technology platform, has been used for the first time in a spinal surgery in the United States.

28 Oct 2009

Shire receives European approval for FOSRENOL

Shire plc, the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL(R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1.78mmol/L (5.5mg/dL).

28 Oct 2009

Hope for lung cancer patients

Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year. It is also estimated that lung cancer will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting from breast, colon and prostate cancers combined.

27 Oct 2009

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

27 Oct 2009

Millennium Research Group to introduce bone morphogenetic proteins in South Korea

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite controversy surrounding bone morphogenetic proteins (BMPs) in the US, they will be introduced into South Korea over the next year and experience double-digit growth in Australia, driving the Asia Pacific bone graft substitute market through 2013.

27 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

FDA orders spinal system manufacturers to conduct postmarket surveillance studies on their products

The U.S. Food and Drug Administration today ordered manufacturers of certain types of pedicle screw systems, called dynamic stabilization systems, to conduct postmarket surveillance studies to collect clinical data on a number of potential safety issues, including fusion rates and frequency of additional surgeries.

27 Oct 2009

First child with a surgically implanted artificial humerus doing well after a year

When little Mark Blinder was diagnosed with a rare bone cancer, doctors at Lucile Packard Children's Hospital gave his parents three agonizing options: amputate the affected arm at the shoulder, irradiate the tumor and risk a second malignancy, or try a limb-preserving surgery that had never been attempted in a toddler.

27 Oct 2009

Protein crucial for insulin regulation may play a role in diabetes

A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes.

27 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

Japanese Patent granted for Pharmalink AB's Nefecon

Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China.

26 Oct 2009

Millions of children in the US suffer from suboptimal levels of vitamin D

Millions of children in the United States between the ages of 1 and 11 may suffer from suboptimal levels of vitamin D, according to a large nationally representative study published in the November 2009 issue of Pediatrics, accompanied by an editorial.

26 Oct 2009

DaVita to demonstrate clinical outcomes, patient care and nutrition through 43 abstracts

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research®, today announced that company representatives will deliver 43 abstracts—40 posters and three oral presentations—at this year’s American Society of Nephrology’s (ASN) Renal Week to be held in San Diego, Calif., from Oct. 27 – Nov. 1, 2009.

24 Oct 2009

Doctoral candidate sheds new light on the biology of Leishmania parasites

Professor Albert Descoteaux's team at Centre INRS - Institut Armand-Frappier has gained a better understanding of how the Leishmania donovani parasite manages to outsmart the human immune system and proliferate with impunity, causing visceral leishmaniasis, a chronic infection that is potentially fatal if left untreated.

24 Oct 2009